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ABSTRACT: There is a lack of high-quality evidence on what treatment should be used in children
with properly characterised severe, therapy-resistant asthma. Data have to be largely extrapolated
from trials in children with mild asthma, and adults with severe asthma. Therapeutic options can be
divided into medications used in lower doses for children with less severe asthma, and those used
in other paediatric diseases but not for asthma (for example, methotrexate). In the first category are
high-dose inhaled corticosteroids (ICS) (f2,000 mg?day-1 fluticasone equivalent), oral
prednisolone, the anti-immunoglobulin (Ig)E antibody omalizumab, high-dose long-acting b2-
agonists, low-dose oral theophylline and intramuscular triamcinolone. If peripheral airway
inflammation is thought to be a problem, the use of fine-particle ICS or low-dose oral
corticosteroids may be considered. More experimental therapies include oral macrolides,
cyclosporin, cytotoxic drugs such as methotrexate and azathioprine, gold salts, intravenous
infusions of Ig, subcutaneous b2-agonist treatment and, in those sensitised to fungi, oral antifungal
therapy with itraconazole or voriconazole. Those with recurrent severe exacerbations, particularly
in the context of good baseline asthma control, are particularly difficult to treat; baseline control and
lung function must be optimised with the lowest possible dose of ICS, and allergen triggers and
exposures minimised. The use of high-dose ICS, leukotriene receptor antagonists or both at the
time of exacerbations can be considered. There is no evidence regarding which therapeutic option
to recommend. Better evidence is required for all these treatment options, underscoring the need
for the international and co-ordinated approach which we have previously advocated.
KEYWORDS: Cyclosporin, long-acting b-agonist, methotrexate, omalizumab, prednisolone,
steroid sparing
T
wo previous reviews in this Series [1, 2]
described the approach to the child with
problematic severe asthma, and the pro-
cesses by which the truly severe, therapy-resis-
tant asthmatic children are identified. This
review addresses the treatment options to be
considered. Almost without exception, the level
of evidence is poor and, except for omalizumab,
there are no good quality randomised controlled
trials. Given the paucity of information in pae-
diatric severe asthma, we have to extrapolate from
data in adults with severe asthma, and any data in
children with mild-to-moderate asthma not con-
trolled on low-dose inhaled corticosteroids (ICS).
Studies in adults will only be mentioned very
briefly to give context. Unless otherwise stated, all
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PubMed searches are limited to human studies in children of all
ages and to articles written in English. Therapeutic options can
be divided into those used in lower doses for children with less
severe asthma and those used in other paediatric diseases (for
example, methotrexate), but not usually for asthma. It is
assumed for the purposes of this review that the child has
already undergone a detailed evaluation process [1, 2] and is
already taking ICS, and has trialled at least two add-on therapies
(long-acting b-agonists (LABA) and leukotriene receptor anta-
gonists (LTRA)). We review what is known about the treatment
of distal airway inflammation, and also the vexed problem of
the child with apparently well-controlled asthma who has
severe exacerbations. Finally, we will discuss what is known
about monitoring treatment.
CONVENTIONAL ASTHMA MEDICATIONS
The first step is always to ensure that standard therapies are
optimised. It is important to realise that, whereas prolonged
poor baseline control may be a risk factor for exacerbations [3],
good baseline control does not prevent the child having exacer-
bations, and no study has succeeded in completely abolishing
exacerbations by any strategy. Treatment of exacerbations and
the exacerbating phenotype are discussed in a separate section.
A summary flow chart of recommendations for treatment is
given in figure 1.
High-dose conventional ICS
The level of the plateau of the dose–response curve to ICS in
children is a matter of debate. There is marked variation across
Europe in the definition of high-dose ICS. Here, we arbitrarily
define high-dose ICS as either 500 mg?day-1 fluticasone propio-
nate (FP) equivalent, or 800 mg?day-1 beclomethasone (BDP),
and low dose as f100 mg?day-1 FP or 200 mg?day-1 BDP. In the
majority of children, it may be as low as 200 mg day-1 FP [4].
High doses (.500 mg?day-1) of mainly FP have been associated
with severe hypoglycaemia secondary to adrenal failure [5, 6].
However, there is reason to believe that in some children,
higher than conventional doses of ICS (.800 mg?day-1 BDP
equivalent) may be beneficial and (perhaps) safe. First, ster-
oid resistance is a spectrum, rather than an all-or-nothing
phenomenon. In vitro, incubation of peripheral blood mono-
nuclear cells with interleukin (IL)-2 and IL-4 leads to relative
steroid insensitivity, which can be overcome by higher doses of
dexamethasone [7, 8]. Secondly, high doses may be less well
absorbed from the airway, at least in adults with asthma [9, 10].
An intravenous dose of FP was cleared equally rapidly by
asthmatics and volunteers, but after both groups inhaled
1,000 mg of FP, the area under the curve for blood levels was
significantly lower in the asthmatics, implying a lesser absor-
ption from the airway than in the controls. This implies, but
does not prove, that appropriate high doses of ICS, in
proportion to the degree of airway inflammation, may be safer
than is thought, and that it is only doses disproportionately
high compared with the level of severity which are dangerous.
A Cochrane review found few studies of high-dose ICS
relevant to really severe asthma in children [11]. However,
there was some evidence that those on oral prednisolone were
able to reduce their prednisolone dosage if they used higher
than conventional ICS doses. A clear need for more data was
identified. Given the lack of evidence, it is difficult to make
firm recommendations. In an asthmatic child dependent on
oral corticosteroids (OCS), it would seem reasonable to try to
reduce oral intake by increasing ICS, perhaps to as high as
2,000 mg day-1, but reduce the ICS dose if oral steroid reduction
is not possible. The use of these high doses of ICS should only
occur under the very careful supervision of a specialist
paediatric pulmonologist. Although careful surveillance is
mandatory, how best and how frequently to monitor adrenal
function, cataract formation and bone mineral density cannot
be determined at the present time (this monitoring is un-
necessary at or below daily ICS doses of 400 mg?day-1 FP).
Recommendations
Given the lack of evidence, it is difficult to make firm
recommendations and more studies are needed. There are
very few children who benefit from ICS doses higher than FP
500 mg?day-1. Increasing doses of ICS (up to ,2,000 mg?day-1
FP) can be tried, in particular in parallel with an attempt to
taper oral prednisolone. If significant clinical benefits are seen,
the dose should be gradually tapered to the lowest dose which
will maintain these benefits. If no benefits are seen the dose
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FIGURE 1. Suggested sequence for consideration of therapy for severe
steroid-resistant asthma. BDP: beclomethasone dipropionate; LABA: long-acting
b2-agonist; LTRA: leukotriene receptor antagonist; ICS: inhaled corticosteroids;
SMART: symbicort maintenance and reliever therapy; SAFS: severe asthma with
fungal sensitisation; MTX: methotrexate; CyA: cyclosporine A.
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should be reduced to the daily dose used prior to the increase.
There is no need to routinely monitor for adverse systemic
effects at ICS daily doses of f400 mg. It is not known whether
and how routine monitoring for adverse systemic effects should
be carried out at higher doses. At a minimum, height should be
measured at each visit and plotted on a growth chart.
Oral corticosteroids
As for most other drugs the clinical benefits of OCS in children
with asthma uncontrolled by ICS, LABA and LTRA are not well
studied, but this therapy is often considered the next step in
treatment recommendations. There is insufficient evidence in the
literature to recommend a starting dose, or how quickly to taper
OCS once control has been achieved. There is no evidence
suggesting that, in the child with repeated exacerbations
mandating oral prednisolone bursts, the prescription of daily or
alternate day low-dose OCS will prevent these exacerbations. If
regular OCS are contemplated, perhaps a reasonable starting dose
might be 0.5 mg?kg-1 daily of prednisolone, tapering as symptoms
permit, but there is no evidence base for this figure. There is no
evidence base to recommend trial duration, but most would use
14 days, stopping the medication if there is no significant benefit.
If there is a response, the dose should be minimised, but adequate
to control symptoms; a recommendation for an upper dose limit
cannot be given. OCS (continuous or intermittent) is associated
with an increased risk of fracture and cataracts in children [12]
and continuous treatment also with increased risk of adrenal
insufficiency and growth retardation [13, 14].
Recommendations
Given the lack of evidence, it is difficult to make firm recom-
mendations and more studies are needed. A therapeutic trial of
prednisolone at an initial daily dose of ,0.5 mg?kg-1 alternate
days should be tried. If significant clinical benefits are seen, the
dose should be gradually tapered to the lowest dose which will
maintain these benefits. This could involve alternate day dosing.
If the therapy is given long term, the most common side-effects
should be monitored, but exactly how is not known. However,
measurement of height, urinalysis for sugar, and blood pressure
measurement should be mandatory at every clinic visit.
Anti-immunoglobulin E antibody
This expensive therapy has become popular despite the
inconvenience of administration and the need for observation
after each injection. It is a logical option in children with true
severe, therapy-resistant asthma who have been through the
detailed assessments described previously [1, 2, 15] and who
meet the following criteria: 1) ongoing chronic symptoms or
severe exacerbations despite high-dose medication, or adequate
control of asthma only at the cost of unacceptable side-effects; 2)
known immunoglobulin (Ig)E-mediated sensitisation to one or
more aero-allergens; and 3) every reasonable effort has been
made to reduce the environmental allergen burden. Thus, the
child allergic to cats who continues to own pet cats should not be
considered for treatment in our view, even despite proven
efficacy in cat allergic patients [16]. The upper limit of IgE
recommended for therapy has just been raised to 1,300 IU.
However, despite this, substantial numbers of children will
have higher levels [17]; whether they will still benefit from
therapy is controversial.
Omalizumab has proven to be safe and beneficial in children in
trials of 1-yr duration. The long-term safety and efficacy has not
yet been validated. Two randomised, placebo-controlled studies
in children aged 6–12 yrs (n5961 in total) with moderate-to-
severe asthma, showed in summary a significant reduction in
ICS dose and number of exacerbations and improvement in
asthma-related quality of life [18, 19]. Omalizumab was safe and
well tolerated in children when used for f1 yr [20]. There were
no serious treatment-related events [18, 19, 21]. Many studies of
older children also included adults, making the purely
paediatric number effects difficult to separate out [22, 23].
Nonetheless, there is sufficient evidence of efficacy in terms of
reduction in exacerbations and medication use, and improve-
ment in quality of life [19, 24, 25] for this therapy to be
recommended in children with atopic allergic asthma aged
o6 yrs if they meet clinical criteria and have an appropriate
level of IgE. However, long-term safety and efficacy of
omalizumab has not been determined. In a small sub-study, a
fall in the exhaled nitric oxide fraction (FeNO), comparable to
that achieved with ICS, was observed [26], in keeping with the
known effect on airway eosinophilia in adults [27]. There are no
tests which can currently be recommended in order to predict
who will respond to omalizumab [28]. Cost–benefit analysis
suggests a fiscal saving if it is given to children with five or more
admissions, cumulatively 20 days or more in hospital [29].
Recommendations
Omalizumab should be tried in children with poor asthma
control and/or exacerbations in spite of daily or alternate day
OCS treatment or treatment with high doses of ICS or ICS plus
LABA or LTRA. Such trials should precede other steroid-sparing
agents in children fulfilling the criteria for omalizumab treatment.
Treatment of distal inflammation
The distal airways are difficult to study, both pathologically and
physiologically. Early studies using transbronchial biopsy (TBB)
[30–32] suggested that distal inflammation was a feature, in
particular, of nocturnal asthma and could be much more severe
than proximal inflammation, although this is controversial [33].
The risks of TBB [34] make it an unattractive routine investigative
modality in children. However, distal inflammation may be
studied by partitioning exhaled nitric oxide (NO) into proximal
(JNO) and distal (CALV) fractions by measuring NO production at
multiple flow rates [35, 36]. The relationship between NO and
eosinophilic inflammation is particularly loose in patients using
high-dose ICS or OCS [37, 38]. It is not clear whether distal
inflammation is an intrinsic part of severe, therapy-resistant
asthma or reflects poor distal airway deposition of conventional
ICS. There are two possible approaches to targeting the distal
airways, either using OCS and relying on airway perfusion or the
use of small particle ICS such as QVAR
TM or ciclesonide [39, 40],
which may have enhanced distal airway deposition. In an adult
study poorly controlled asthmatics had elevated CALV which
correlated with bronchoalveolar lavage eosinophil count and was
reduced by oral prednisolone [41]. In a paediatric study, CALV
was also elevated in poorly controlled asthma [42]. However, the
role of distal inflammation in severe asthma is still contentious.
Recommendations
In a child with uncontrolled severe, therapy-resistant asthma
and who has evidence of distal airway disease (elevated CALV,
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air trapping on a high-resolution computed tomography scan or
abnormal lung clearance index), a trial of fine particle ICS or oral
prednisolone should be considered. The optimal trial duration is
not known, but should probably be at least 3 months.
The symbicort maintenance and reliever therapy regime
This relies on the use of a single inhaler (budesonide and
formoterol) as regular therapy and for exacerbation of symp-
toms. In the original trials, the dose used was budesonide 100 mg
and formoterol 6 mg once daily, with extra doses as needed, and
there was a reduction in exacerbation rates with no increase in
ICS dose, compared with conventional regimes. This regime has
mainly been studied in adults with markedly uncontrolled
asthma in spite of regular ICS or ICS/LABA combination
treatment and a certain number of exacerbations have always
been one of the inclusion criteria [43]. The study population was
highly selected, and exhibited an average forced expired
volume in 1 s (FEV1) reversibility of .20%. The studies have
consistently found that the strategy significantly reduced the
risk of severe exacerbations, whereas the effects on asthma
control have generally been small. Thus, only a mean of 18% of
over 16,000 patients studied were well controlled after 1 yr of
treatment. The same seems to be the case for adolescents where
the symbicort maintenance and reliever therapy (SMART)
regime had no significant effects on hospitalisations, asthma
control days, need for rescue treatment and symptom-free days
[44]. The optimal SMART daily dose for children with severe
asthma has not been studied. It must be said that the SMART
regime is still controversial, and data proving efficacy compared
with conventional regimes are lacking [45–50]. Overdosing with
LABA, both in the population as a whole and in those carrying
particular b2-receptor polymorphisms has been raised as a
concern and it is recommended that LABA should never be
given without ICS [51]. A recent meta-analysis of more than
100,000 patients did not detect any general adverse effects [52],
although the authors stated that more data were needed.
Therefore, it seems rather unlikely that treatment with ICS/
LABA combinations in a single inhaler is associated with any
clinically important adverse effects. The evidence in children
with the Arg16/Arg16 polymorphism is less reassuring [53]
than in adults [54], with some evidence of an increased risk of
exacerbation on LABA.
Recommendations
More studies are needed in children. A trial of the SMART
regime, probably using the budesonide 200 mg/formoterol
6 mg turbohaler, is worth considering in children with severe,
therapy-resistant asthma in whom severe exacerbations are
still a problem.
Low-dose theophylline
Theophylline has been rediscovered as a potentially beneficial
agent in asthma. It had largely fallen into disrepute because of
side-effects, drug interactions (for example, with erythromycin)
and the need to monitor blood levels. However, low-dose
theophylline, aiming at blood levels below the conventional
therapeutic range (5–10 instead of 10–20 mol?L-1) has a number
of immunomodulatory properties which might make it attrac-
tive. In adult studies, it inhibits the late-phase response to aero-
allergen challenge [55]. It accelerates neutrophil apoptosis,
making it of particular interest in neutrophilic asthma [56, 57].
Theophylline withdrawal leads to a rise in peripheral blood
monocytes (CD14+, activated CD4+ T-lymphocytes (CD4+/
CD25+) and activated CD8+ T-cells (CD8+/HLA-DR+)), with a
rise in these cells in the bronchial mucosa [58]. Theophylline may
downregulate inflammatory gene expression via effects on histone
acetylases (HATs) and histone deacetylases (HDACs) [59]. HATs
are increased and HDACs reduced in asthma, and this is reversed
by glucocorticoids as well as theophylline, leading to a nuclear
factor-kB dependent reduction in IL-8, tumour necrosis factor
(TNF)-a and granulocyte-macrophage colony-stimulating factor
in response to lipopolysaccharide. Furthermore, theophyllines
may prevent downregulation of the b-receptor by b2-agonists [60].
It is thus suggestive that at least some forms of acquired steroid
resistance may be reversed by low-dose theophylline. However,
the molecular mechanisms of steroid resistance in children with
severe, therapy-resistant asthma are not known and may be
different to adults, and generally the clinical effects of adding
theophylline to ICS have been small [61, 62].
Recommendations
More studies are needed before firm recommendations can be
made. In the meantime, a therapeutic trial with low-dose
theophylline could be tried in individual patients with severe,
therapy-resistant asthma. The duration of such a trial is not
known, but it should probably be of some months.
Intramuscular triamcinolone
We have discussed elsewhere the use of a single dose of
triamcinolone as a therapeutic trial of steroid resistance [63].
Since acquired steroid resistance is a spectrum, not an all-or-
nothing phenomenon like congenital resistance [64], it could be
argued that multiple injections may be more appropriate,
although the dose and time interval is unknown. There has
been a suggestion from an adult trial that depot triamcinolone
may be better than OCS in the control of asthma, with fewer
side-effects [65]. Comparisons of the two strategies are probably
dogged by differences in adherence. Depot triamcinolone has
the same class effects as prednisolone, with the additional risk of
subcutaneous atrophy at the injection site [66]. Two small
paediatric studies suggest that triamcinolone may improve
symptoms and reduce airway inflammation in children with
severe asthma [67, 68].
Recommendations
The exact place of depot triamcinolone as a treatment of severe,
therapy-resistant asthma is not clear. It would seem reasonable
to offer a trial for a finite period, in particular to those in whom
poor adherence to prednisolone is suspected, which may
perhaps demonstrate that the child is truly steroid sensitive if
the steroids are actually administered.
EXPERIMENTAL THERAPIES
There are no agreed guidelines on the selection of suitable
patients or the order in which these therapies should be tried.
The use of any of these should be preceded by very careful dis-
cussions with the child and family, and rigorous safety
monitoring should be in place.
Macrolide antibiotics
Macrolides have an array of immunomodulatory activities, in
addition to their antibacterial effects [69–71]. They have
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principally found a role in neutrophilic airway diseases, such as
diffuse panbronchiolitis (in which their effects have been most
dramatic) [72–74], cystic fibrosis [75–78], and non-cystic fibrosis
bronchiectasis [79–81]. There is much less evidence in asthma
and very little evidence in true severe, therapy-resistant asthma,
despite a long standing interest in the role of macrolides in
severe asthma, starting with the early studies of troleandomy-
cin. This macrolide was initially popular as a steroid-sparing
agent, although liver function abnormalities were a worry [82–
85]. However, in a placebo-controlled study of troleandomycin
in steroid-dependent asthma, there was no benefit in terms of
steroid reduction, with if anything a more adverse profile of
steroid side-effects in the active group [86]. This led to the
suggestion that troleandomycin only exerted a ‘‘steroid-spar-
ing’’ effect by reducing the catabolism of steroids, merely
increasing half-life and exposure to toxicity in the face of an
apparently reassuring dose reduction. The increase in steroid
side-effects was confirmed in other studies, again using methyl
prednisolone [87, 88]. A pharmacokinetic study showed that
troleandoycin, even in low doses, reduced methyl prednisolone
clearance by 60%, but had no effect on prednisolone pharma-
cokinetics [89]. Troleandomycin is no longer recommended for
asthma treatment, although the dataset was small (90 analysable
patients) [90]. Clarithromycin also had no effect on prednisolone
clearance or drug levels, but decreased methyl prednisolone
clearance by 65%, with an increase in blood levels [91]. This
suggests that any macrolides may increase the half-life of
methyl prednisolone.
The possible role of atypical respiratory infections in asthma led
to exploration of the possible benefits of the antibiotic effects of
macrolides. There is some evidence in adults that infection with
Chlamydia pneumoniae and Mycoplasma pneumoniae may be
important, although this is still controversial. A randomised
placebo-controlled, double-blind trial of clarithromycin in 55
adult asthmatic patients showed that only those given clari-
thromycin and with PCR positivity to Mycoplasma or Chlamydia
had improvements in spirometry; all those treated with
clarithromycin showed a reduction in pro-inflammatory cyto-
kines [92]. Conversely, a trial of roxithromycin in adult
asthmatics with serological evidence of C. pneumoniae infection
showed only a transient beneficial effect on asthma control [93].
The macrolide telithromycin was shown be beneficial in acute
asthma in a large randomised controlled trial, and the effect was
independent of Mycoplasma or Chlamydia status [94]. With the
realisation that there were neutrophilic asthma phenotypes [95],
a number of mechanistic studies were performed in adult
asthmatics. Macrolides have been shown to reduce neutrophilic
inflammation [96], bronchial responsiveness [97–99] and airway
oedema [100], and increase the steroid responsiveness of
peripheral blood lymphocytes [101].
Mechanistic data in children are confined to small studies, which
have shown that macrolides reduce induced sputum neutro-
philia, reduce cytokine production by epithelial cells and
improve bronchial hyperresponsiveness [102–104]. There is
one large clinical study in children, which compared azithro-
mycin with montelukast in children with asthma uncontrolled
on ICS and LABAs [105]. The study was futile and under-
powered, as recognised by the investigators, because most of
those screened either did not have asthma or were not compliant
with standard medications. However, the authors considered
that even if the recruitment targets had been met, a benefit
would have been unlikely.
Recommendations
Macrolides, such as azithromycin and clarithromycin, have
immunomodulatory properties which make them attractive
agents to explore in children with severe, therapy-resistant
asthma. There is a paucity of efficacy data in asthma, but
macrolides are safer than the cytotoxic agents. Whether their
antibiotic properties could be important is an open question,
but the recent finding of a rich bacterial flora in the lower
airways using 16s rRNA methodology, and its alteration in
children with asthma [106] suggests that these could be even
more important than the immunological effects. It is reason-
able to give a trial of macrolides, particularly in children with
neutrophilic asthma. More data are needed to establish
whether other groups may also benefit.
Cyclosporin
A Cochrane review [107] identified three adequate trials of
cyclosporin in 106 adults with steroid-dependent asthma (98
patients analysable). There was a very small effect on steroid
reduction, of questionable significance. There have been no new
randomised trials since the review. One paediatric case series
reported benefit in terms of OCS reduction in three out of five
children [108]. Whether in the future nebulised cyclosporin may
be beneficial with fewer side-effects is an important unanswered
question [109, 110].
Recommendations
Paediatric data are very scanty, but a trial of cyclosporin could
be considered in children with persistent eosinophilic airway
inflammation despite OCS therapy, or requirement of unac-
ceptably high levels of OCS to control their asthma.
Cytotoxics
Methotrexate and azathioprine have been used in severe
corticosteroid-dependent asthma. If their use is contemplated
in children, careful monitoring along standard lines is essential.
There are no special monitoring requirements in the asthmatic
child.
Methotrexate
In adults, the Cochrane review of 10 trials in 185 subjects
suggested that there was overall a small benefit (reduction of
OCS dose by ,5 mg?day-1), with risk of hepatotoxicity such
that risks probably out-weighed benefits [111]. It is probable
that within the group data there were individuals who did
well. We identified three open-label trials including 20 children
with steroid-dependent asthma aged 3–16 yrs treated with
methotrexate. Significant side-effects are uncommon [112–114].
Recommendations
A trial of methotrexate can be considered in children with
steroid-resistant airway inflammation and those requiring high-
dose OCS to maintain control of asthma.
Azathioprine
A PubMed search using the terms ‘‘Asthma’’ and ‘‘Azathio-
prine’’ yielded no papers. The Cochrane review [115] found
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only two studies of 23 adult patients which did not give enough
evidence to recommend treatment.
Recommendations
Azathioprine cannot be recommended in children with asthma.
Gold salts
There are limited randomised controlled study data showing a
steroid-sparing effect of auranofin in adult asthmatics [116–119].
There are no published paediatric data.
Recommendations
Given the need for detailed monitoring, the low chance of
benefit, and the risk of adverse events, auranofin cannot be
recommended in children with severe, therapy-resistant asthma.
Ig infusions
Adult studies are conflicting. One randomised controlled study,
which included adults and children, demonstrated reduction in
OCS requirements with no loss of control [120], whereas a
second (also spanning the age range) was terminated prema-
turely because of adverse events, and showed no benefits [121].
There are four purely paediatric series, in which ,40 children
received Ig infusions [122–125]. One open-label study reported
that six out of 14 children could reduce their OCS, but two of the
original 20 were withdrawn because of severe side-effects [122].
An open-label study of eight children documented reduction in
steroid dosage and, interestingly, skin test reactivity [123]. By
contrast, a randomised controlled trial in 31 children showed no
benefits in asthma-related end-points, but did show in the
treated group an attenuation of the severity but not the number
of upper respiratory tract infections [124]. In a methodological
study, analysis of bronchial biopsies before and after treatment
showed reduction of all cell types, especially mucosal CD3, CD4
and CD25 positive T-cells, with reduced peripheral blood T-cell
activation [125].
Recommendations
There is no adequately powered paediatric trial to support the
use of infusion of i.v. Ig in asthma. Consideration of its use
should probably be confined to asthmatic children who are
OCS dependent. Side-effects, including aseptic meningitis are
not rare. A trial of i.v. infusion of Ig may be justified in some
children.
Anti-fungal therapy
In adult practice, and to a lesser extent in paediatrics, the
concept of severe asthma with fungal sensitisation (SAFS) is
becoming established. There is considerable evidence that
fungal sensitisation and exposure are associated with increased
morbidity and severity of asthma, including really severe
exacerbations [126–130]. If a diagnosis of SAFS is being
considered, sensitisation should be tested both with skin prick
tests (SPT) and specific radioallergen absorbent tests (RAST)
since concordance between the two varies from 70 to 80% [130,
131]. SAFS is diagnosed in a patient of any age with evidence of
sensitisation on either SPT or RAST to at least one fungus
(table 1) [130]. A randomised, double-blind, placebo-controlled
clinical trial in adults showed some benefit in terms of improved
quality of life and a reduction in IgE with itraconazole therapy
[130]. This was more a proof of concept trial, with small
numbers (,60 in total) rather than a study which showed major
clinical benefit. The evidence in children is limited to isolated
case reports [132]. The approach seems relatively safe.
Recommendations
Children with possible SAFS, who are not controlled after
eliminating as far as possible any moulds in the environment,
may be candidates for a trial of oral itraconazole or even vori-
conazole if symptoms persist, although the cost and side-effect
profile of the latter mandate caution. The interaction between ICS
and itraconazole leading to Cushing’s syndrome should not be
forgotten [133].
Subcutaneous terbutaline infusion
There is limited literature (n541) on adults using subcuta-
neous infusion of terbutaline [134, 135] or salbutamol [136]. In
children, fewer than 20 cases have been reported [137, 138].
Only one was a double-blind study [136]. There is obviously a
strong placebo effect, and also concern about b-receptor down-
regulation with this approach. One group suggested that this
could be ameliorated by concomitant oral theophylline treat-
ment [60]. Additional problems include local reactions [134],
risk of hypokalaemia [139, 140] and a skeletal myositis with
elevation of creatine kinase [141].
Recommendations
There is little evidence to recommend treatment with contin-
uous subcutaneous terbutaline. It might be reasonable to trial it
in selected children in whom airway inflammation has been
clearly demonstrated to have been controlled by ICS or OCS,
and in whom there is marked documented peak flow varia-
bility, despite appropriate use of inhaled LABA, especially
including the SMART regime. We recommend commencing
this treatment in hospital, using a double-blinded protocol. The
child has four treatment periods, separated by wash-out
periods, with detailed monitoring of peak flow in particular.
The child and family know that only the ward pharmacist will
know which the active treatment period is. All too often, the
child gets better in hospital irrespective of treatment, as
medication is given regularly and the influence of adverse
home environmental influences wanes. In a few highly
selected children, the benefits of continuous subcutaneous
infusion of terbutaline may outweigh the considerable incon-
venience of treatment.
TREATMENT OF THE EXACERBATING PHENOTYPE
Increasingly, guidelines have separated baseline asthma
control from exacerbations. For example, persistently poor
baseline control and reduction in lung function are associated
TABLE 1 Fungi implicated in severe asthma with fungal
sensitisation
Aspergillus fumigatus
Alternaria alternate
Cladosporium herbarum
Penicillium chrysogenum
Candida albicans
Trichophyton mentagrophytes
Botrytis cinerea
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with increased risk of exacerbations [142–146]. However, it is
possible to have apparently perfect baseline control with severe
viral exacerbations, and increasing conventional medications to
the limit does not abolish all exacerbations. A previous very
severe exacerbation is a risk factor for future exacerbations,
making these children a high-risk group. There is clearly
overlap, but children with excellent baseline control still
exacerbate, and there is no evidence that increasing ICS dose
between exacerbations in a well-controlled child is an effective
strategy. There is also physiological evidence that the two are not
the same [147]. Poor baseline control is characterised by
symptoms and marked diurnal variability in peak flow, and
responds well to usually low doses of ICS. Exacerbations are
usually virally mediated [148], and characterised by an abrupt
drop in peak flow, with little diurnal variability. Acute
exacerbations may also be the result of overwhelming allergen
exposure, as in the Barcelona soya bean epidemic [149] or
thunderstorm asthma [150]. Although management should
include every effort to optimise asthma control and lung
function, and reduce airway inflammation in between exacer-
bations, virus-induced exacerbations cannot always be pre-
vented, and can cause acute drops in lung function even on the
background of apparent excellent baseline control (but much
less frequently in controlled than uncontrolled patients).
Although in pre-school children with purely episodic, viral
wheeze there is no evidence of an interaction between viral
infection and allergens [151], the interaction is clearly present
in school age children. One study showed that the combination
of viral upper respiratory tract infection, allergen sensitisation,
and high level of allergen exposure in the child’s home was
strongly predictive of an exacerbation severe enough to merit
admission to hospital [152]. Although no study has convin-
cingly shown that reducing allergen burden reduces exacer-
bations in children with severe, therapy-resistant asthma, such
an approach, described in more detail elsewhere [2, 15], would
seem sensible. This and other work has shown that low-dose
ICS reduce the risk of exacerbations in children with mild-to-
moderate asthma [142, 152]. There is some evidence that the
use of oral LTRA [153], or very high dose ICS [154, 155], at the
time of exacerbation may reduce the need for OCS in exacer-
bations. There is no study exploring the effects of high-dose
ICS and LTRA together, but the combination could be
considered if appropriate.
In adult practice, the exacerbating phenotype has been
characterised as having few symptoms but discordantly
marked ongoing eosinophilic airway inflammation between
exacerbations [156]. It is this highly selected group that seem to
respond to anti-IL5 therapy [157, 158]. The extent to which this
phenotype exists in children and, if it does, whether it will
respond to anti-IL5 therapy, remains to be researched.
Finally, the rare child who has catastrophic drops in lung
function over a few minutes on the background of apparent
excellent control (type 2 brittle asthma) may on an anecdotal
basis benefit from being given injectable adrenaline (EpipenTM)
for emergency treatment of these deteriorations, enabling very
rapid administration of a sympathomimetic (a and b) intramus-
cularly while more selective inhaled treatment is being
prepared. Food allergy is common in this group and should
actively be sought as part of the treatment programme [159, 160].
Recommendations
Children who have had previous severe exacerbations are at
high risk for a future severe exacerbation and should be closely
monitored. Every effort should be made to optimise baseline
control and lung function; to identify allergic triggers and mini-
mise allergen exposure; and to ensure low-dose ICS are being
taken. The use of ever-increasing doses of ICS between
exacerbations in children with good baseline control and lung
function is not recommended. There is not enough evidence in
children to recommend monitoring sputum eosinophils in these
children. A trial of high-dose ICS with or without LTRAs at the
first sign of an exacerbation may be considered.
MONITORING THERAPY
In the context of adult and less severe paediatric asthma, the
use of FeNO has not been shown to improve daily asthma
control or reduce the daily dose of ICS [161] (two studies
found no change, two found an increase and one a reduction
in the daily dose of ICS, all of them used different algorithms
which made pooling of the data impossible [162–167]).
However, some trials using tools such as FeNO, induced
sputum or bronchial responsiveness to monitor asthma
suggested that using inflammometry may lead to better
control without the need for bigger ICS doses [164, 168, 169].
From adult data, it would appear that the greatest benefit of
inflammometry is in those with more severe disease [170]. In
children, exhaled NO has been used to predict successful
reduction in ICS dose [171] and relapse after stopping ICS
altogether [172]. The only study which has tested this in
children with severe, therapy-resistant asthma showed only
trends in benefit for inflammometry [173]. Reasons may have
included the need to use NO in children who could not
produce a sputum sample, despite the poor relationship
between them in this population [174]; the much greater
instability of sputum cellular phenotypes in children com-
pared with adults [175]; and possibly, the need to make
monthly rather than three monthly measurements (post hoc
there was a benefit for inflammometry, but only in the month
immediately after the measurements were made).
Recommendations
More work is needed to determine how best to monitor
treatment to minimise side-effects and maximise benefits in
this challenging group of patients.
SUMMARY AND CONCLUSIONS
We have reviewed the limited evidence for the various
treatment options for children with severe, therapy-resistant
asthma. It cannot be over-stressed that before employing any
of them, every effort must be made to determine that the child
truly has therapy-resistant asthma and that all the basic aspects
of management have been correct [1, 2, 15]. A summary of our
recommendations is given in figure 1. Therapeutic options can
be divided into medications used in lower doses for children
with less severe asthma, and those used in other paediatric
diseases but not for asthma (for example, methotrexate). In the
first category are high-dose ICS (f2,000 mg?day-1 fluticasone
equivalent), oral prednisolone, the anti-IgE antibody omalizu-
mab, high-dose LABAs, low-dose oral theophylline, and intra-
muscular triamcinolone. If peripheral airway inflammation
is thought to be a problem, the use of fine particle ICS or
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low-dose OCS may be considered. More experimental thera-
pies include oral macrolides, cyclosporin, cytotoxic drugs such
as methotrexate and azathioprine, gold salts, Ig, subcutaneous
b2-agonist treatment and, in those sensitised to fungi, oral
antifungal therapy with itraconazole or voriconazole. Those
with recurrent severe exacerbations, particularly in the context
of good baseline asthma control, are particularly difficult to
treat; baseline control and lung function must be optimised
with the lowest possible dose of ICS, and allergen triggers and
exposures minimised. The use of high-dose ICS, LTRAs or
both at the time of exacerbations can be considered. There is no
evidence on which therapeutic option to recommend.
In the future, it will be important to ensure that children are
part of clinical trials in severe, therapy-resistant asthma. Recent
developments in Europe will hopefully increase the likelihood
of this [176].There is clearly a tension here, for example, anti-
TNF-a strategies looked promising initially in severe therapy-
resistant asthma [177], but subsequent studies have largely
shown that the risk outweighs the benefit [178]. It is thus good
that they were never formally trialled in children, although of
course there is a nagging doubt, as children and adults are
different, and a useful paediatric treatment may have been
discarded. However, it is important that more promising
therapies, such as anti-IL5 [157, 158] and bronchial thermo-
plasty [179, 180] are trialled in suitable children. Since it is
highly unlikely that one centre will see enough patients to do a
single-centre trial, the need for international collaboration with
standard assessments of the children across Europe, is under-
lined [1, 2, 181, 182].
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